Burlington, Mass. – October 30, 2026 -- Azenta (Nasdaq: AZTA) has secured an exclusive license to Elegen Corp.'s cell-free DNA synthesis platform and acquired SynPlexity Inc., two moves aimed at expanding the gene synthesis and discovery capabilities of its GENEWIZ business.

Burlington, Mass. – September 08, 2026 -- Azenta, Inc. (Nasdaq: AZTA) has received full repayment, ahead of maturity, of a $35 million secured vendor loan tied to its divestiture of B Medical Systems S.à r.l., closing out the transaction with the entire $63 million purchase price now collected in cash.